March 3, 2017 Associate Professor David Ackerley. Credit: Victoria University <\/p>\n
Research led by Associate Professor David Ackerley, director of Victoria's Biotechnology programme, has underpinned the development of a new form of chemotherapy that exclusively targets cancer cells. <\/p>\n
A key goal of this chemotherapy is a more targeted treatment method that results in fewer side effects for cancer patients. <\/p>\n
To achieve this goal, Associate Professor Ackerley and his team engineered enzymes that can transform a relatively safe and non-toxic compound (a \"pro-drug\") into a drug that is highly toxic to cancer cells. <\/p>\n
The genes encoding these enzymes are delivered to cancer cells using viruses or bacteria that are only able to replicate in tumours. <\/p>\n
The pro-drug the team worked with is called PR-104A, and was developed by scientists at the University of Auckland, including Associate Professor Ackerley's collaborators on this study, Associate Professor Adam Patterson and Dr Jeff Smaill. <\/p>\n
\"The enzyme we started with was moderately active with PR-104A,\" says Associate Professor Ackerley. \"However, this was purely by chancenature has never evolved enzymes to recognise these very artificial types of molecules. <\/p>\n
\"We reasoned that by mimicking evolution in the laboratoryby introducing random mutations into the gene encoding our target enzyme, then selecting the tiny minority of variants where chance mutations had improved activitywe might eventually achieve a more specialised enzyme that could more effectively activate PR-104A.\" <\/p>\n
Not only is the team's artificially evolved enzyme significantly better at activating PR-104A within living cells, it also addresses another major problemhow to keep track of the microbes in patients to make sure they are only infecting cancerous cells. <\/p>\n
\"A unique aspect of our work is that our enzymes can also trap radioactive molecules called 'positron emission tomography (PET) probes',\" says Associate Professor Ackerley. \"We hope that this will allow a clinician to put a patient in a full body PET scanner to safely identify the regions where the microbes are replicating.\" <\/p>\n
The team's research has been published in this month's edition of high-profile research journal Cell Chemical Biology, and has been supported by several New Zealand funding agencies including the Marsden Fund managed by the Royal Society of New Zealand, the Health Research Council of New Zealand and the New Zealand Cancer Society. <\/p>\n
In ongoing work, Dr Smaill and Associate Professor Patterson have been developing more effective pro-drugs to partner with Associate Professor Ackerley's enzymes. The team has been collaborating with groups at the University of Nottingham in the United Kingdom and Maastricht University in the Netherlands, aiming to progress the therapy into clinical trials in cancer patients. <\/p>\n
Explore further: Wave of interest in new cancer therapy <\/p>\n
More information: Janine N. Copp et al. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy, Cell Chemical Biology (2017). DOI: 10.1016\/j.chembiol.2017.02.005<\/p>\n
Using viruses and bacteria that normally cause disease to cure disease is an apparent contradiction, but its fundamental to the work being carried out by Dr. David Ackerley. <\/p>\n
Colon cancer cells that are pretreated with an ingredient found in cruciferous vegetables are more likely to be killed by a cancer drug that is currently in development, found ETH scientists. This is one of only a few examples ... <\/p>\n
To better understand how cancer initiates and spreads, Yale associate professor of pathology Qin Yan turned to the field of epigenetics, which examines changes in the expression of genes and proteins that do not affect the ... <\/p>\n
Research at Victoria University of Wellington could lead to a new generation of antibiotics, helping tackle the global issue of 'superbugs' that are resistant to modern medicine. <\/p>\n
Unprecedented images of cancer genome-mutating enzymes acting on DNA provide vital clues into how the enzymes work to promote tumor evolution and drive poor disease outcomes. These images, revealed by University of Minnesota ... <\/p>\n
Scientists from Trinity College Dublin have uncovered a new class of compounds - glyconaphthalimides - that can be used to target cancer cells with greater specificity than current options allow. <\/p>\n
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy, in cancer survivors, according to a study by researchers at The University ... <\/p>\n
Research led by Associate Professor David Ackerley, director of Victoria's Biotechnology programme, has underpinned the development of a new form of chemotherapy that exclusively targets cancer cells. <\/p>\n
Physicians currently have no targeted treatment options available for women diagnosed with an aggressive form of breast cancer known as triple-negative breast cancer (TNBC), leaving standard-of-care chemotherapies as a first ... <\/p>\n
A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified a mechanism by which cancer cells ... <\/p>\n
It's what's missing in the tumor genome, not what's mutated, that thwarts treatment of metastatic melanoma with immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in ... <\/p>\n
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid leukemia (AML), a fast-growing cancer of bone marrow and blood cells and the ... <\/p>\n
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more <\/p>\n
<\/p>\n
See the rest here: <\/p>\n
Mimicking evolution to treat cancer - Medical Xpress<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" March 3, 2017 Associate Professor David Ackerley. Credit: Victoria University Research led by Associate Professor David Ackerley, director of Victoria's Biotechnology programme, has underpinned the development of a new form of chemotherapy that exclusively targets cancer cells. A key goal of this chemotherapy is a more targeted treatment method that results in fewer side effects for cancer patients Continue reading